ClinicalTrials.gg
RecruitingNCT06084481Updated Oct 14, 2026

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

A Phase 1 interventional study of ABBV-400 and Itraconazole (ITZ) in Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma and Biliary Tract Cancers, sponsored by AbbVie. Recruiting at 54 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Oct 14, 2026Site recruiting status changed8 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
325
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Carcinoma, Hepatocellular by AbbVie — 1 open to participants now, 4 under way, 1 of them phase 3. Carcinoma, Hepatocellular · AbbVie.

Planned enrollment
2nd of 10
325 · median 110
Started
2023
with 1 other
Phase 1
7 of 10
1 open now
Registered
8th of 10
by date

Among the 10 studies in Carcinoma, Hepatocellular by AbbVie, this one is the 2nd largest by planned enrollment, is one of 2 that started in 2023, is one of 7 in phase 1, and was the 8th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

1 of the 10 studies in Carcinoma, Hepatocellular by AbbVie is open now, in 8 countries.

By country, each count listing its studies:

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Hepatocellular by AbbVie, or all of them as a file.
02

Study summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors.

ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Cohorts 1-8 receive ABBV-400 alone (monotherapy), cohort 9 receives ABBV-400 with a strong CYP3A3 inhibitor (ITZ), and cohort 10 receives ABBV-400 with bevacizumab. All cohorts are followed by a safety follow-up period. Approximately 325 adult participants with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative breast cancer (TNBC), hormone receptor+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (hormone receptor-positive [HR+]/HER2-breast cancer [BC]), head and neck squamous-cell-carcinoma (HNSCC), Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer, or advanced solid tumors, will be enrolled in the study in approximately 54 sites worldwide.

In cohorts 1-8, participants with the following advanced solid tumor indications: HCC, PDAC, BTC, ESCC, TNBC, HR+/HER2-BC, HNSCC, and PROC/primary peritoneal/fallopian tube cancer will receive intravenous (IV) ABBV-400 monotherapy, in cohort 9 participants will receive IV ABBV-400 and an oral solution of ITZ, and in cohort 10 participants will receive IV ABBV-400 and IV bevacizumab, for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Biliary Tract Cancers
  • Esophageal Squamous Cell Carcinoma
  • Triple Negative Breast Cancer
  • Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
  • Head and Neck Squamous-Cell Carcinoma
  • Platinum Resistant High Grade Epithelial Ovarian Cancer

Keywords

  • Hepatocellular Carcinoma
  • Pancreatic Ductal Adenocarcinoma
  • Biliary Tract Cancers
  • Esophageal Squamous Cell Carcinoma
  • Triple Negative Breast Cancer
  • Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
  • Head and Neck Squamous-Cell Carcinoma
  • Platinum Resistant High Grade Epithelial Ovarian Cancer
  • Solid Tumors
  • Advanced Solid Tumors
  • ABBV-400
  • bevacizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Laboratory values meeting the criteria laid out in the protocol.
  • per (RECIST) version 1.1.
  • Documented diagnosis of locally advanced or hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), squamous cell carcinoma of the esophagus, (ESCC), triple negative breast cancer (TNBC), hormone receptor+/-breast cancer (HR+/HER2-BC), head and neck squamous-cell-carcinoma (HNSCC), or Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer (by World Health Organization [WHO] criteria). Participant meets the criteria for disease activity laid out in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Have received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any therapy within 28 days or 5 half-lives of the drug (whichever is shorter) prior to the first dose of ABBV-400. Palliative radiation therapy for bone, skin, or subcutaneous with 10 fractions or less is permitted and not subject to a .
  • Unresolved AEs > Grade 1 from prior anticancer therapy.
  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic , or any evidence of active ILD or pneumonitis, including but not limited to those listed in the protocol.
  • History of clinically significant, intercurrent lung-specific illnesses, including those laid out in the protocol.
  • Untreated brain or meningeal metastases (i.e., participants with history of metastases are eligible provided they do not require ongoing steroid treatment for cerebral edema and have shown clinical and radiographic stability for at least 14 days after definitive therapy). Participants may continue on antiepileptic therapy if required.
  • History of other active , with the exception of those laid out in the protocol.
  • Any , connective tissue or inflammatory disorders with documented or suspicious pulmonary involvement at screening (i.e., rheumatoid arthritis, Sjogren's, sarcoidosis etc.), and prior pneumonectomy.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
325 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Hepatocellular Carcinoma (HCC)

    Participants with HCC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400

  • Experimental
    Cohort 2: Pancreatic Ductal Adenocarcinoma (PDAC)

    Participants with PDAC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400

  • Experimental
    Cohort 3: Biliary Tract Cancers (BTC)

    Participants with BTC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400

  • Experimental
    Cohort 4: Esophageal Squamous Cell Carcinoma, (ESCC)

    Participants with ESCC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400

  • Experimental
    Cohort 5: Triple Negative Breast Cancer (TNBC)

    Participants with TNBC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400

  • Experimental
    Cohort 6: Hormone Receptor+/HER2-breast Cancer (HR+/HER2-BC)

    Participants with HR+/HER2-BC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400

  • Experimental
    Cohort 7: Head and Neck Squamous-cell-carcinoma (HNSCC)

    Participants with HNSCC will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400

  • Experimental
    Cohort 8: PROC/Primary Peritoneal/Fallopian Tube Cancer

    Participants with Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer will receive ABBV-400 for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400

  • Experimental
    Cohort 9: Drug-Drug Interaction

    Participants with advanced or metastatic solid tumors will receive ABBV-400 and a strong CYP3A4 inhibitor (ITZ) for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400 · Drug: Itraconazole (ITZ)

  • Experimental
    Cohort 10: PROC/Primary Peritoneal/Fallopian Tube Cancer

    Participants with PROC/primary peritoneal/fallopian tube cancer will receive ABBV-400 in combination with bevacizumab for up to 3 years during and up to the treatment period with an additional safety follow-up period of up to 2 years.

    Drug: ABBV-400 · Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR defined as percentage of participants with confirmed best overall response of confirmed partial response (PR) or better per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to 36 Months

  2. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to 36 Months

  3. Maximum Observed Concentration (Cmax) of ABBV-400 Conjugate

    Cmax of ABBV-400 conjugate.

    Time frame: Up to 36 Months

  4. AUC from Time 0 to the End of Dosing Interval (AUCtau) of ABBV-400 Conjugate

    AUCtau of ABBV-400 conjugate.

    Time frame: Up to 36 Months

Secondary outcomes

  1. Duration of Response (DOR) for Participants with Confirmed Complete Response (CR)/PR

    DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to RECIST 1.1 criteria to disease progression or death of any cause, whichever occurs earlier.

    Time frame: Up to 36 Months

  2. Clinical Benefit Rate

    CBR is defined as the proportion of participants with a best overall response of stable disease at least 5 weeks post first dose, confirmed CR or PR per investigator review according to RECIST, version 1.1

    Time frame: Up to 36 Months

  3. Progression-free Survival (PFS)

    PFS is defined as time from first study treatment to a documented disease progression according to RECIST, version 1.1, as determined by the investigator, or death due to any cause, whichever occurs earlier.

    Time frame: Up to 36 Months

  4. Overall Survival (OS)

    OS is defined as time from first study treatment to death due to any cause.

    Time frame: Up to 36 Months

  5. Cmax of ABBV-400

    Cmax of ABBV-400.

    Time frame: Up to 36 Months

  6. Time to Cmax (Tmax) of ABBV-400

    Tmax of ABBV-400.

    Time frame: Up to 36 Months

  7. Area Under the Plasma Concentration-time Curve (AUC) for Total Antibody Concentration

    AUC for total antibody concentration.

    Time frame: Up to 36 Months

  8. Total Antibody Drug Conjugate (ADC) Concentration

    Total ADC concentration.

    Time frame: Up to 36 Months

  9. Plasma Concentrations of Unconjugated Topoisomerase 1 (Top1) Inhibitor Payload

    Plasma concentrations of unconjugated Top1 inhibitor payload.

    Time frame: Up to 36 Months

  10. Antidrug Antibody (ADA)

    Incidence and concentration of anti-drug antibodies.

    Time frame: Up to 36 Months

  11. Neutralizing Antidrug Antibody (nADA)

    Incidence and concentration of neutralizing anti-drug antibodies.

    Time frame: Up to 36 Months

  12. Tmax of ABBV-400 Conjugate

    Tmax of ABBV-400 conjugate.

    Time frame: Up to 36 Months

  13. Tmax of ABBV-400 Unconjugated

    Tmax of ABBV-400 unconjugated.

    Time frame: Up to 36 Months

  14. Terminal Phase Elimination Half-Life (t1/2) of ABBV-400 Conjugate

    t1/2 of ABBV-400 conjugate.

    Time frame: Up to 36 Months

  15. t1/2 of ABBV-400 Unonjugated

    t1/2 of ABBV-400 unconjugated.

    Time frame: Up to 36 Months

  16. Volume of Distribution at Steady State (Vss) of ABBV-400 Conjugate

    Vss of ABBV-400 conjugate.

    Time frame: Up to 36 Months

  17. Vss of ABBV-400 Unconjugated

    Vss of ABBV-400 unconjugated.

    Time frame: Up to 36 Months

  18. Total Body Clearance at Steady State (CLss) of ABBV-400 Conjugate

    CLss of ABBV-400 conjugate.

    Time frame: Up to 36 Months

  19. CLss of ABBV-400 Unconjugated

    CLss of ABBV-400 unconjugated.

    Time frame: Up to 36 Months

07

Study locations

47 of 54 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Sep 2027, 46 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 46 months is close to that.

Counting every sponsor, half of 249 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2023
First posted
Oct 16, 2023
StartActual
Nov 9, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
8 sites added, 8 sites removed. 39 sites changed recruiting status (39 now recruiting)
Show 39 sites
  • City of Hope National Medical Center /ID# 258645 · Duarte, United StatesActive, not recruiting→Recruiting
  • UCSF Medical Center - Mount Zion /ID# 257705 · San Francisco, United StatesCompleted→Recruiting
  • Sarah Cannon Research Institute at HealthONE - Denver /ID# 258926 · Denver, United StatesActive, not recruiting→Recruiting
  • University of Chicago Medical Center /ID# 258197 · Chicago, United StatesActive, not recruiting→Recruiting
  • START Midwest /ID# 256581 · Grand Rapids, United StatesActive, not recruiting→Recruiting
  • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 255132 · New York, United StatesActive, not recruiting→Recruiting
  • Duke Cancer Center /ID# 255129 · Durham, United StatesActive, not recruiting→Recruiting
  • Univ Hosp Cleveland /ID# 257706 · Cleveland, United StatesActive, not recruiting→Recruiting
  • Lifespan Cancer Institute at Rhode Island Hospital /ID# 257693 · Providence, United StatesActive, not recruiting→Recruiting
  • MUSC Hollings Cancer Center /ID# 257935 · Charleston, United StatesCompleted→Recruiting
  • Prisma Health /ID# 257697 · Greenville, United StatesCompleted→Recruiting
  • MD Anderson Cancer Center /ID# 255131 · Houston, United StatesCompleted→Recruiting
  • Univ Texas HSC San Antonio /ID# 257708 · San Antonio, United StatesActive, not recruiting→Recruiting
  • Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 262771 · Fairfax, United StatesCompleted→Recruiting
  • Chris O'Brien Lifehouse /ID# 262765 · Camperdown, AustraliaCompleted→Recruiting
  • Austin Health /ID# 256635 · Heidelberg, AustraliaCompleted→Recruiting
  • Rabin Medical Center. /ID# 256650 · Petah Tikva, IsraelCompleted→Recruiting
  • The Chaim Sheba Medical Center /ID# 255731 · Ramat Gan, IsraelCompleted→Recruiting
  • Tel Aviv Sourasky Medical Center /ID# 258931 · Tel Aviv, IsraelCompleted→Recruiting
  • Rambam Health Care Campus /ID# 256649 · Haifa, IsraelActive, not recruiting→Recruiting
  • Hadassah Medical Center-Hebrew University /ID# 256655 · Jerusalem, IsraelActive, not recruiting→Recruiting
  • NHO Nagoya Medical Center /ID# 261001 · Nagoya, JapanCompleted→Recruiting
  • Aichi Cancer Center Hospital /ID# 256679 · Nagoya, JapanCompleted→Recruiting
  • National Cancer Center Hospital East /ID# 258934 · Kashiwa-shi, JapanActive, not recruiting→Recruiting
  • Kyoto University Hospital /ID# 256680 · Kyoto, JapanActive, not recruiting→Recruiting
  • Shizuoka Cancer Center /ID# 257789 · Sunto-gun, JapanActive, not recruiting→Recruiting
  • National Cancer Center Hospital /ID# 261136 · Chuo-Ku, JapanActive, not recruiting→Recruiting
  • Pan American Center for Oncology Trials - Rio Piedras /ID# 262903 · Rio Piedras, Puerto RicoCompleted→Recruiting
  • Inje University Haeundae Paik Hospital /ID# 260118 · Busan, South KoreaCompleted→Recruiting
  • Seoul National University Hospital /ID# 255730 · Seoul, South KoreaCompleted→Recruiting
  • …and 9 more on the registry record
Show 8 added (5 United States, 2 Spain, 1 Japan)
  • Florida Cancer Specialists- Sarasota Cattlemen /ID# 261569 · Sarasota, United States
  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378 · Chicago, United States
  • Washington University /ID# 257379 · St Louis, United States
  • SCRI Oncology Partners /ID# 261568 · Nashville, United States
  • South Texas Accelerated Research Therapeutics /ID# 260404 · San Antonio, United States
  • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 257788 · Koto-ku, Japan
  • Clinica Universidad de Navarra - Pamplona /ID# 264042 · Pamplona, Spain
  • Clinica Universidad de Navarra - Madrid /ID# 256703 · Madrid, Spain
Show 8 removed
  • Florida Cancer Specialists /ID# 261569 · Sarasota, United States
  • Northwestern University Feinberg School of Medicine /ID# 257378 · Chicago, United States
  • Washington University-School of Medicine /ID# 257379 · St Louis, United States
  • Tennessee Oncology-Nashville Centennial /ID# 261568 · Nashville, United States
  • START-San Antonio · San Antonio, United States
  • The Cancer Institute Hospital Of JFCR /ID# 257788 · Koto-ku, Japan
  • Clinica Universidad de Navarra - Pamplona /ID# 256703 · Pamplona, Spain
  • Clinica Universidad de Navarra - Madrid /ID# 264042 · Madrid, Spain
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    8 sites added, 8 sites removed. 39 sites changed recruiting status (39 now recruiting)
    Show 39 sites
    • City of Hope National Medical Center /ID# 258645 · Duarte, United StatesActive, not recruiting→Recruiting
    • UCSF Medical Center - Mount Zion /ID# 257705 · San Francisco, United StatesCompleted→Recruiting
    • Sarah Cannon Research Institute at HealthONE - Denver /ID# 258926 · Denver, United StatesActive, not recruiting→Recruiting
    • University of Chicago Medical Center /ID# 258197 · Chicago, United StatesActive, not recruiting→Recruiting
    • START Midwest /ID# 256581 · Grand Rapids, United StatesActive, not recruiting→Recruiting
    • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 255132 · New York, United StatesActive, not recruiting→Recruiting
    • Duke Cancer Center /ID# 255129 · Durham, United StatesActive, not recruiting→Recruiting
    • Univ Hosp Cleveland /ID# 257706 · Cleveland, United StatesActive, not recruiting→Recruiting
    • Lifespan Cancer Institute at Rhode Island Hospital /ID# 257693 · Providence, United StatesActive, not recruiting→Recruiting
    • MUSC Hollings Cancer Center /ID# 257935 · Charleston, United StatesCompleted→Recruiting
    • Prisma Health /ID# 257697 · Greenville, United StatesCompleted→Recruiting
    • MD Anderson Cancer Center /ID# 255131 · Houston, United StatesCompleted→Recruiting
    • Univ Texas HSC San Antonio /ID# 257708 · San Antonio, United StatesActive, not recruiting→Recruiting
    • Inova Schar Cancer Institute - Fairfax - Innovation Park Drive /ID# 262771 · Fairfax, United StatesCompleted→Recruiting
    • Chris O'Brien Lifehouse /ID# 262765 · Camperdown, AustraliaCompleted→Recruiting
    • Austin Health /ID# 256635 · Heidelberg, AustraliaCompleted→Recruiting
    • Rabin Medical Center. /ID# 256650 · Petah Tikva, IsraelCompleted→Recruiting
    • The Chaim Sheba Medical Center /ID# 255731 · Ramat Gan, IsraelCompleted→Recruiting
    • Tel Aviv Sourasky Medical Center /ID# 258931 · Tel Aviv, IsraelCompleted→Recruiting
    • Rambam Health Care Campus /ID# 256649 · Haifa, IsraelActive, not recruiting→Recruiting
    • Hadassah Medical Center-Hebrew University /ID# 256655 · Jerusalem, IsraelActive, not recruiting→Recruiting
    • NHO Nagoya Medical Center /ID# 261001 · Nagoya, JapanCompleted→Recruiting
    • Aichi Cancer Center Hospital /ID# 256679 · Nagoya, JapanCompleted→Recruiting
    • National Cancer Center Hospital East /ID# 258934 · Kashiwa-shi, JapanActive, not recruiting→Recruiting
    • Kyoto University Hospital /ID# 256680 · Kyoto, JapanActive, not recruiting→Recruiting
    • Shizuoka Cancer Center /ID# 257789 · Sunto-gun, JapanActive, not recruiting→Recruiting
    • National Cancer Center Hospital /ID# 261136 · Chuo-Ku, JapanActive, not recruiting→Recruiting
    • Pan American Center for Oncology Trials - Rio Piedras /ID# 262903 · Rio Piedras, Puerto RicoCompleted→Recruiting
    • Inje University Haeundae Paik Hospital /ID# 260118 · Busan, South KoreaCompleted→Recruiting
    • Seoul National University Hospital /ID# 255730 · Seoul, South KoreaCompleted→Recruiting
    • …and 9 more on the registry record
    Show 8 added (5 United States, 2 Spain, 1 Japan)
    • Florida Cancer Specialists- Sarasota Cattlemen /ID# 261569 · Sarasota, United States
    • Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378 · Chicago, United States
    • Washington University /ID# 257379 · St Louis, United States
    • SCRI Oncology Partners /ID# 261568 · Nashville, United States
    • South Texas Accelerated Research Therapeutics /ID# 260404 · San Antonio, United States
    • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 257788 · Koto-ku, Japan
    • Clinica Universidad de Navarra - Pamplona /ID# 264042 · Pamplona, Spain
    • Clinica Universidad de Navarra - Madrid /ID# 256703 · Madrid, Spain
    Show 8 removed
    • Florida Cancer Specialists /ID# 261569 · Sarasota, United States
    • Northwestern University Feinberg School of Medicine /ID# 257378 · Chicago, United States
    • Washington University-School of Medicine /ID# 257379 · St Louis, United States
    • Tennessee Oncology-Nashville Centennial /ID# 261568 · Nashville, United States
    • START-San Antonio · San Antonio, United States
    • The Cancer Institute Hospital Of JFCR /ID# 257788 · Koto-ku, Japan
    • Clinica Universidad de Navarra - Pamplona /ID# 256703 · Pamplona, Spain
    • Clinica Universidad de Navarra - Madrid /ID# 264042 · Madrid, Spain
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06084481
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Nov 9, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telisotuzumab adizutecan

Start the discussion